Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroAction Plus intensive smoking cessation intervention with varenicline
NL-OMON38232Phase 4Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of varenicline in nicotine dependence and cardiac morbidity (2 arms), sponsored by Imperial College London. Primary endpoints: 7-day point prevalence smoking abstinence at 16 weeks and Long-term non-smoking prevalence. Started Jun 2010; status: active, not recruiting.
02
Drugs
varenicline
03
Conditions
nicotine dependencecardiac morbidity
Beyond the preview
Go deeper on NL-OMON38232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38232.